-+ 0.00%
-+ 0.00%
-+ 0.00%
Immutep Reports 81.1% 12-Month Disease-Free Survival in Phase II Soft Tissue Sarcoma Trial
Share
Listen to the news
Immutep Reports 81.1% 12-Month Disease-Free Survival in Phase II Soft Tissue Sarcoma Trial
  • Immutep presented encouraging disease-free survival results from its Phase II EFTISARC-NEO soft tissue sarcoma trial at CTOS 2026.
  • The study evaluated eftilagimod alfa with Keytruda and radiotherapy before surgery in patients with high-risk, resectable disease.
  • Stronger post-treatment immune responses were associated with better disease-free survival; longer-term findings remain preliminary.
  • A registration-directed trial is targeted for the second half of 2027, subject to regulatory interactions, manufacturing timelines, partnering arrangements and available resources.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611181912PRIMZONEFULLFEED9880992) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending